High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.
Humans
Mozambique
/ epidemiology
COVID-19
/ epidemiology
Seroepidemiologic Studies
Adult
Adolescent
Child, Preschool
Middle Aged
Young Adult
Child
SARS-CoV-2
/ immunology
Female
Male
Infant
Antibodies, Viral
/ blood
Rural Population
Infant, Newborn
Aged
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
COVID‐19
Mozambique
SARS‐CoV‐2
antibodies
seroprevalence
serosurvey
sub‐Saharan Africa
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
08
03
2024
received:
03
08
2023
accepted:
19
05
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
5
6
2024
Statut:
ppublish
Résumé
Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination. We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0-19, 20-39, 40-59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR. SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals < 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys. A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.
Sections du résumé
BACKGROUND
BACKGROUND
Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination.
METHODS
METHODS
We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0-19, 20-39, 40-59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR.
RESULTS
RESULTS
SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals < 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys.
CONCLUSIONS
CONCLUSIONS
A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13332Subventions
Organisme : COVID-19 Solidarity Response Fund
Organisme : German Federal Ministry of Health (BMG) COVID-19 Research and Development Fund
Organisme : European and Developing Countries Clinical Trials Partnership
ID : RIA2020EF-3005-MozCOVID
Organisme : Bill and Melinda Gates Foundation
ID : OPP1126780
Informations de copyright
© 2024 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
World Health Organization, “WHO Coronavirus (COVID‐19) Dashboard,” published (2023), accessed December 12, 2023, https://covid19.who.int/region/afro/country/mz.
J. Adams, M. J. MacKenzie, A. K. Amegah, et al., “The Conundrum of Low COVID‐19 Mortality Burden in Sub‐Saharan Africa: Myth or Reality?” Global Health: Science and Practice 9, no. 3 (2021): 433–443, https://doi.org/10.9745/GHSP‐D‐21‐00172.
S. K. Tessema and J. N. Nkengasong, “Understanding COVID‐19 in Africa,” Nature Reviews. Immunology 21, no. 8 (2021): 469–470, https://doi.org/10.1038/s41577‐021‐00579‐y.
I. Bergeri, H. C. Lewis, L. Subissi, et al., “Early Epidemiological Investigations: World Health Organization UNITY Protocols Provide a Standardized and Timely International Investigation Framework During the COVID‐19 Pandemic,” Influenza and Other Respiratory Viruses 16, no. 1 (2022): 7–13, https://doi.org/10.1111/irv.12915.
D. McConnell, C. Hickey, N. Bargary, et al., “Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS‐CoV‐2,” International Journal of Environmental Research and Public Health 18, no. 9 (2021): 4640, https://doi.org/10.3390/ijerph18094640.
M. V. Murhekar and H. Clapham, “COVID‐19 Serosurveys for Public Health Decision Making,” The Lancet Global Health 9, no. 5 (2021): e559–e560, https://doi.org/10.1016/S2214‐109X(21)00057‐7.
S. Selvaraju, M. S. Kumar, J. W. V. Thangaraj, et al., “Population‐Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India,” Emerging Infectious Diseases 27, no. 2 (2021): 586–589, https://doi.org/10.3201/eid2702.203938.
C. S. Benn, A. Salinha, S. Mendes, et al., “SARS‐CoV‐2 Serosurvey Among Adults Involved in Healthcare and Health Research in Guinea‐Bissau, West Africa,” Public Health 203 (2022): 19–22, https://doi.org/10.1016/j.puhe.2021.11.013.
C. Meinus, R. Singer, B. Nandi, et al., “SARS‐CoV‐2 Prevalence and Immunity: A Hospital‐Based Study from Malawi,” International Journal of Infectious Diseases 116 (2022): 157–165, https://doi.org/10.1016/j.ijid.2021.12.336.
D. Alber, F. C. Haidara, J. Luoma, et al., “SARS‐CoV‐2 Infection and Antibody Seroprevalence in Routine Surveillance Patients, Healthcare Workers and General Population in Kita Region, Mali: An Observational Study 2020–2021,” BMJ Open 12, no. 6 (2022): e060367, https://doi.org/10.1136/bmjopen‐2021‐060367.
WHO, “Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID‐19) Infection,” World Heal Organ. 2020, (2020), https://www.who.int/publications/i/item/WHO‐2019‐n.
I. N. de Saúde, Boletim Diário Coronavirus (COVID19) N832, (2022). Maputo.
F. J. Martínez‐Martínez, A. J. Massinga, Á. De Jesus, et al., “Tracking SARS‐CoV‐2 Introductions in Mozambique Using Pandemic‐Scale Phylogenies: A Retrospective Observational Study,” The Lancet Global Health 11, no. 6 (2023): e933–e941, https://doi.org/10.1016/S2214‐109X(23)00169‐9.
N. Ismael, S. van Wyk, H. Tegally, et al., “Genomic Epidemiology of SARS‐CoV‐2 During the First Four Waves in Mozambique,” PLOS Global Public Health 3, no. 3 (2023): e0001593, https://doi.org/10.1371/journal.pgph.0001593.
M. Eccleston‐Turner and H. Upton, “International Collaboration to Ensure Equitable Access to Vaccines for COVID‐19: The ACT‐Accelerator and the COVAX Facility,” The Milbank Quarterly 99, no. 2 (2021): 426–449, https://doi.org/10.1111/1468‐0009.12503.
Programa Alargado de Vacinação, “Plano Nacional de Vacinação Contra COVID‐19,” (2021), https://www.misau.gov.mz/index.php/covid‐19‐planos‐nacionais‐e‐vacinacao?download=1093:plano‐nacional‐de‐resposta‐a‐pandemia‐do‐covid‐19‐2021.
M. Sidat and I. Capitine, “Infeção por SARS‐CoV‐2 em Moçambique: a epidemiologia e os avanços alcançados com a vacinação contra a COVID‐19,” Anais Do Instituto de Higiene e Medicina Tropical 21 (2022): 90–98, https://doi.org/10.25761/anaisihmt.432.
E. Mathieu, H. Ritchie, E. Ortiz‐Ospina, et al., “A Global Database of COVID‐19 Vaccinations,” Nature Human Behaviour 5, no. 7 (2021): 947–953, https://doi.org/10.1038/s41562‐021‐01122‐8.
E. Mathieu, H. Ritchie, L. Rodés‐Guirao, et al., “Coronavirus Pandemic (COVID‐19),” Our World Data, (2020).
C. Royo‐Cebrecos, D. Vilanova, J. López, et al., “Mass SARS‐CoV‐2 Serological Screening, a Population‐Based Study in the Principality of Andorra,” The Lancet Regional Health–Europe 5 (2021): 100119, https://doi.org/10.1016/j.lanepe.2021.100119.
Instituto Nacional de Saúde (INS), Ministério da Saúde (MISAU), Instituto Nacional de Estatística (INE). “Inquérito Sero‐Epidemiológico de SARS‐CoV‐2 InCOVID‐19, 2020,” (2020).
C. Sacoor, A. Nhacolo, D. Nhalungo, et al., “Profile: Manhiça Health Research Centre (Manhiça HDSS),” International Journal of Epidemiology 42, no. 5 (2013): 1309–1318, https://doi.org/10.1093/ije/dyt148.
A. Nhacolo, E. Jamisse, O. Augusto, et al., “Cohort Profile Update: Manhiça Health and Demographic Surveillance System (HDSS) of the Manhiça Health Research Centre (CISM),” International Journal of Epidemiology 50 (2021): 395–398, https://doi.org/10.1093/ije/dyaa218.
World Health Organization (WHO), “The Unity Studies: WHO Sero‐Epidemiological Investigations Protocols. Coronavirus Disease (COVID‐19) Technical Guidance: The Unity Studies: Early Investigation Protocols.”
Note WG, “Laboratory Testing for Coronavirus Disease (COVID‐19) in Suspected Human Cases: Interim Guidance, 11 Setember 2020,” World Health Organization, (2020).
Benjing Wantai Biological Pharmacy Enterprise Co, “L. WANTAI Total Ab ELISA for Antibody Levels Product,” Published online (2020).
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd, “WANTAI SARS‐CoV‐2 Ab ELISA,” Wantai BioPharm, (2020), 5:5–7.
P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J. G. Conde, “Research Electronic Data Capture (REDCap)—A Metadata‐Driven Methodology and Workflow Process for Providing Translational Research Informatics Support,” Journal of Biomedical Informatics 42, no. 2 (2009): 377–381, https://doi.org/10.1016/j.jbi.2008.08.010.
P. A. Harris, R. Taylor, B. L. Minor, et al., “The REDCap Consortium: Building an International Community of Software Platform Partners,” Journal of Biomedical Informatics 95 (2019): 103208, https://doi.org/10.1016/j.jbi.2019.103208.
I. N. de Saúde, “Vigilância Genómica Do SARS‐CoV‐2 Em Moçambique ‐ Boletim n 001/2021,” Maputo, (2021).
Observatório Nacional de Saúde (ONS), “COVID‐19 Em Moçambique – Relatório Do 1o Ano (2020–2021),” (2021).
M. R. O. Chisale, S. Ramazanu, S. E. Mwale, et al., “Seroprevalence of Anti‐SARS‐CoV‐2 Antibodies in Africa: A Systematic Review and Meta‐Analysis,” Reviews in Medical Virology 32, no. 2 (2022): e2271, https://doi.org/10.1002/rmv.2271.
A. Rostami, M. Sepidarkish, A. Fazlzadeh, et al., “Update on SARS‐CoV‐2 Seroprevalence: Regional and Worldwide,” Clinical Microbiology and Infection 27, no. 12 (2021): 1762–1771, https://doi.org/10.1016/j.cmi.2021.09.019.
M. Azami, Y. Moradi, A. Moradkhani, and A. Aghaei, “SARS‐CoV‐2 Seroprevalence Around the World: An Updated Systematic Review and Meta‐Analysis,” European Journal of Medical Research 27, no. 1 (2022): 81, https://doi.org/10.1186/s40001‐022‐00710‐2.
J. Kleynhans, S. Tempia, N. Wolter, et al., “SARS‐CoV‐2 Seroprevalence in a Rural and Urban Household Cohort During First and Second Waves of Infections, South Africa, July 2020–March 2021,” Emerging Infectious Diseases 27, no. 12 (2021): 3020–3029, https://doi.org/10.3201/eid2712.211465.
F. Awartani, N. M. Qutob, and M. R. Asia, “Seroprevalence of SARS‐CoV‐2 Antibodies Among Vaccinated and Non‐Vaccinated Adults in the West Bank: Results of a Repeated Cross‐Sectional Study,” Vaccine 10, no. 8 (2022): 1332, https://doi.org/10.3390/vaccines10081332.